AOB

[la-onda]

AOB: Jefferies Starts @ Buy; Sets Tgt @ $20; Analyst Notes
Wednesday, November 21, 2007 08:26ET
Issuer: American Oriental Bioengineering Inc (NYSE: AOB)
Analyst Firm:  Jefferies Group Inc.
Ratings Action: INITIATE
Current Rating: Buy
Target Price Action: INITIATE
Target Price: $20.00

Analyst Comments: AOB has proven its ability to assimilate acquisitions, turning inorganic expansion into a sustainable and value accretive strategy. The firm expects AOB's revenues to expand 32% CAGR over the next three years.

[BigSully1]

ER Thursday

[setravis]

AP
American Oriental Bioengineering shares soar on 1Q earnings
Wednesday May 7, 4:22 pm ET 
American Oriental Bioengineering shares soar on 1st-quarter profits, 2008 earnings outlook


NEW YORK (AP) -- Shares of pharmaceutical company American Oriental Bioengineering Inc. soared Wednesday after the company said its first-quarter profit surged on strong sales of its prescription and over-the-counter products.


Shares of American Oriental rose $2.06, or 22 percent, to close at $11.44. They have traded in a 52-week range of $6.83 to $14.48.

During the quarter, the company earned $9.4 million, or 12 cents per share, compared with $6.4 million, or 10 cents per share, in the prior-year period.

Revenue rose 51 percent to $38.8 million from $25.7 million.

Analysts surveyed by Thomson Financial expected a profit of 12 cents per share on revenue of $38 million.

American Oriental said the increase in revenue resulted from a nearly 72 percent jump in pharmaceutical product sales and a 138 percent increase in over-the-counter product sales.

Chief Executive Officer Tony Liu said that the company projects full-year revenue of at least $245 million, a 50 percent increase over 2007, as well as net income of at least $62 million, which represents a 43 percent increase from 2007.

Brean Murray Carret & Co. analyst Alex Xu said that the company's full-year guidance is conservative.

"Given the company;s aggressive acquisition pipeline, we see potential upside to the guidance," Xu wrote. He has a "Buy" rating on shares and a $19 price target.

______________________________________________________________


Super growth.......
Growing at 30% plus the stock sells at less than 10x expected 2009 earnings. "Medicine from plants" is the play...a big item in China. Stock probably worth 20 bucks now and if the growth rate continues...much higher in a couple of years.

52wk Range: 6.83 - 14.48
Volume: 5,443,441
Avg Vol (3m): 1,214,460
Market Cap: 894.54M
P/E (ttm): 18.85
EPS (ttm): 0.607

Technicals
Last Price Quote is:
22.41%above 13-day MA
26.58%above 50-day MA
RS Rating: 85 

Fundamentals
Key Data:
Market Cap (M): $796.03 
P/E Ratio: 16.55 
PEG Ratio: 0.480769 
Next Earnings: 08/06/2008
Last Analyst Rating: Buy

[BigSully1]

update